Management of Head-and-Neck Cancer during COVID-19 Crisis: A Medical Oncology Perspective

Raja Pramanik; Priyanka Srivastava; Atul Sharma; Prashant Mehta; Amol Patel; Sainath Bhethanbhotla; Bivas Biswas; Atul Batra; Vineet Govinda Gupta; Chandan Krushna Das; Shubh Mahendru

doi:10.4103/ijmpo.ijmpo_134_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 153-155
DOI: 10.4103/ijmpo.ijmpo_134_20

How I Treat

Management of Head-and-Neck Cancer during COVID-19 Crisis: A Medical Oncology Perspective

Raja Pramanik

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Priyanka Srivastava

M.S.Patel Cancer Center, Shree Krishna Hospital and Medical Research Centre, Karamsad, Gujarat, India

,

Atul Sharma

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Prashant Mehta

Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India

,

Amol Patel

Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

,

Sainath Bhethanbhotla

Department of Medical Oncology, Care Cancer Institute, Hyderabad, Telangana, India

,

Bivas Biswas

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Atul Batra

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Vineet Govinda Gupta

Department of Medical Oncology, Artemis Hospital, Gurgaon, Haryana, India

,

Chandan Krushna Das

Regional Cancer Centre, PGI-MER, Chandigarh, India

,

Shubh Mahendru

Department of Surgical Oncology, Ivy Hospital, Ajitgarh, Punjab, India

› Author Affiliations

Abstract

Full Text

References

References
1 Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy [published online ahead of print, 2020 Mar 23]. JAMA. 2020. 10.1001/jama.2020.4683. doi 10.1001/jama.2020.4683
2 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. JAMA 2020; e201585 doi 10.1001/jama.2020.1585
3 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21: e181
4 https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf 356-India-Fact-Sheets. Available from: [Last accessed on 2020 Mar 29]
5 Sharma S, Satyanarayana L, Asthana S, Shivalingesh KK, Goutham BS, Ramachandra S. Oral cancer statistics in India on the basis of first report of 29 population-based cancer registries. J Oral Maxillofac Pathol 2018; 22: 18-26
6 Poddar A, Aranha R, Royam MM, Gothandam KM, Nachimuthu R, Jayaraj R. Incidence, prevalence, and mortality associated with head and neck cancer in India: Protocol for a systematic review. Indian J Cancer 2019; 56: 101-6
7 Denaro N, Merlano MC, Russi EG. Follow-up in head and neck cancer: Do more does it mean do better? A systematic review and our proposal based on our experience. Clin Exp Otorhinolaryngol 2016; 9: 287-97
8 Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19 [published online ahead of print, 2020 Mar 27]. Ann Intern Med 2020; M20-1133 doi: 10.7326/M20-1133
9 Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ. et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: A phase I-II study. J Clin Oncol 1989; 7: 761-8
10 Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R. et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 2011; 22: 2304-9
11 Patil VM, Noronha V, Joshi A, Nayak L, Pande N, Chandrashekharan A. et al. Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer. Indian J Cancer 2017; 54: 25-9
12 Patil VM, Noronha V, Joshi A, Banavali SD, Muddu V, Prabhash K. Preoperative chemotherapy and metronomic scheduling of chemotherapy in locally advanced oral cancers. Oncology 2016; 91 Suppl 1 35-40
13 Sultania M, Deo SV, Shukla NK, Sharma A, Sahu RK, Bhasker S. Neoadjuvant metronomic chemotherapy in locally advanced head and neck cancers – A feasibility study. Eur J Cancer 2017; 72: S106
14 Patil VM, Noronha V, Joshi A, Dhumal S, Mahimkar M, Bhattacharjee A. et al. Phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early-failure oral cancer. J Clin Oncol 2019; 37: 3032-41
15 Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M. et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018; 29: 2208-13